Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
Open Access Publication
Rights and Permissions
Case, J.B., Mackin, S., Errico, J.M. et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun 13, 3824 (2022). https://doi.org/10.1038/s41467-022-31615-7 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Case, James Brett; Mackin, Samantha; Errico, John M; Chong, Zhenlu; Madden, Emily A; Whitener, Bradley; Jung, Ana; Droit, Lindsay; Handley, Scott A; Fremont, Daved H; Virgin, Herbert W; Diamond, Michael S; and et al, "Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains." Nature Communications. 13, 1. 3824 (2022).
41467_2022_31615_MOESM2_ESM.pdf (3310 kB)
Peer Review File
41467_2022_31615_MOESM3_ESM.pdf (1459 kB)
41467_2022_31615_MOESM4_ESM.zip (3860 kB)